Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072890 · ClinicalTrials.gov registry record · Phase 1
Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01072890 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 8 participants.
The verdict
NCT01072890, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of temsirolimus and pazopanib at different doses. Patients who have an advanced cancer that is not felt to benefit from standard treatment or are no longer responding to other treatment will be asked to take part in this study. The study hypothesis is that temsirolimus and pazopanib can be administered safely in combination and that combined targeting of the mammalian target of rapamycin (mTOR) and vascular endothelial growth factor receptor (VEGFR) signaling pathways will be effective in treating patients with advanced solid tumors.
Interventions
- DRUG Temsirolimus, Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01072890
The ClinicalTrials.gov registry entry for NCT01072890 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Temsirolimus, Pazopanib is the first listed.
NCT01072890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01072890 about?
NCT01072890 is a clinical study titled "Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors". The purpose of this study is to test the safety of temsirolimus and pazopanib at different doses. Patients who have an advanced cancer that is not felt to benefit from standard treatment or are no longer responding to other treatment will be asked to take part in this study. The study hypothesis is ...
What is the current status of trial NCT01072890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2010-02. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01072890?
The interventions under investigation include: Temsirolimus, Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01072890?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.